Clostridium perfringens lacking perfringolysin O toxin isolated from preterm infants metabolizes human milk oligosaccharide disialyllacto-N-tetraose to produce metabolites that promote the growth of c...

This postdoctoral research position is part of a Cystic Fibrosis Canada Early Career Investigator Award funded for 3-years led by Dr. Fabrice Jean-Pierre and Dr. Fiona Whelan. The aim of this project is to identify the genetic changes that arise in the Pseudomonas aeruginosa genome following perturbations – such as antibiotic treatment – in an in vitro system. The PDRA will use a large dataset of P. aeruginosa genomes and experimental metadata to predict key mutationsto the organism.

Clostridium perfringens lacking perfringolysin O toxin isolated from preterm infants metabolizes human milk oligosaccharide disialyllacto-N-tetraose to produce metabolites that promote the growth of commensal bifidobacteria, inhibit pathogens and suppress inflammation in an organoid model.

Microbial-based and microorganism-targeting therapies are emerging to prevent or treat preterm infant complications, but more preclinical research and clinical evidence is needed.

A leading young scientist is the first at Newcastle University to win an esteemed Blavatnik award.

Applied Microbiology International member Dr Christopher Stewart of Newcastle University has been named as a finalist for the eighth Blavatnik Awards for Young Scientists in the UK. He is the 2023 win...